Automated cellular imaging system III for assessing HER2 status in breast cancer specimens: Development of a standardized scoring method that correlates with FISH

American Journal of Clinical Pathology

Volumn 132, Issue 1, 2009, Pages 133-138

  Minot, Douglas M ^a   Kipp, Benjamin R ^a   Root, Renee M ^a   Meyer, Reid G ^a   Reynolds, Carol A ^a   Nassar, Aziza ^a   Henry, Michael R ^a   Clayton, Amy C ^a  

^a MAYO CLINIC   (United States)

Author keywords

ACIS; Automation; Herceptin; Immunohistochemistry; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; AUTOMATED CELLULAR IMAGING SYSTEM 3; BREAST BIOPSY; BREAST CANCER; CONTROLLED STUDY; CYTOLOGY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DNA, NEOPLASM; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 67650499944     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCPJV0SKAF2PCMY     Document Type: Article

References (22)

1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
2. Perez EA, Baweja M. HER2-positive breast cancer: current treatment strategies. Cancer Invest. 2008;26:545-552.
3. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells. 1998;16:413-428.
4. Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol. 2006;24:3032-3038.
5. Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the Breast Intergroup Trial N9831. J Natl Cancer Inst. 2002;94:855-857.
6. Bloom K, Harrington D. Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopy. Am J Clin Pathol. 2004;121:620-630.
7. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18-43.
8. Wang S, Saboorian MH, Frenkel EP, et al. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am J Clin Pathol. 2001;116:495-503.
9. Tawfik O, Kimler B, Davis M, et al. Comparison of immunohistochemistry by Automated Cellular Imaging System (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma. Histopathology. 2006;48:258-267.
10. Perez EA, Roche PC, Jenkins RB, et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc. 2002;77:148-154.
11. PathVysion [package insert]. Downers Grove, IL: Vysis; 2001.
12. Tubbs RR, Pettay JD, Roche PC, et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol. 2001;19:2714-2721.
13. Barrett C, Magee H, O'Toole D, et al. Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive or false-negative immunohistochemistry? J Clin Pathol. 2007;60:690-693.
14. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000;18:3651-3664.
15. Bartlett J, Mallon E, Cooke T. The clinical evaluation of HER-2 status: which test to use? J Pathol. 2003;199:411-417.
16. Dowsett M, Bartlett J, Ellis IO, et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol. 2003;199:418-423.
17. Ridolfi RL, Jamehdor MR, Arber JM. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol. 2000;13:866-873.
18. US Food and Drug Administration. 510(k) Summary of Substantial Equivalence, ChromaVision Medical Systems, Inc (Automated Cellular Imaging System). http://www.fda.gov/cdrh/pdf3/k032113.pdf. Accessed February 17, 2009.
19. Dendukuri N, Khetani K, McIsaac M, et al. Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. CMAJ. May 8, 2007;176:1429-1434.
20. Lehr HA, Jacobs TW, Yaziji H, et al. Quantitative evaluation of HER-2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis. Am J Clin Pathol. 2001;115:814-822.
21. Hatanaka Y, Hashizume K, Kamihara Y, et al. Quantitative immunohistochemical evaluation of HER2/neu expression with HercepTest in breast carcinoma by image analysis. Pathol Int. 2001;51:33-36.
22. Skaland I, Ovestad I, Janssen EA, et al. Digital image analysis improves the quality of subjective HER-2 expression scoring in breast cancer. Appl Immunohistochem Mol Morphol. 2008;16:185-190.